Medical Care
Global Microbiome Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 06, 25
- ID: 295150
- Pages: 175
- Figures: 170
- Views: 6
In 2024, the global market size of Microbiome Therapeutics was estimated to be worth US$ 173 million and is forecast to reach approximately US$ 1609 million by 2031 with a CAGR of 38.1% during the forecast period 2025-2031.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Segment by Type
Upper GIT
Lower GIT
Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Microbiome Therapeutics in global and regional level.
Chapter 3: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Therapeutics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Segment by Type
Upper GIT
Lower GIT
Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Microbiome Therapeutics in global and regional level.
Chapter 3: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Therapeutics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Microbiome Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Microbiome Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Market by Application
1.3.1 Global Microbiome Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Microbiome Therapeutics Market Size Estimates and Forecasts
2.2 Microbiome Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global Microbiome Therapeutics Revenue by Region: 2020-2025
2.2.2 Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Microbiome Therapeutics Revenue by Type (2020-2031)
3.1.2 Global Microbiome Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Microbiome Therapeutics Revenue by Application (2020-2031)
3.2.2 Global Microbiome Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Upper GIT of Microbiome Therapeutics Revenue Market Share by Application
3.3.2 Lower GIT of Microbiome Therapeutics Revenue Market Share by Application
4 Global Microbiome Therapeutics by Company
4.1 Global Microbiome Therapeutics Revenue by Company (2020-2025)
4.2 Global Microbiome Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Microbiome Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Microbiome Therapeutics Companies Headquarters & Product Type
4.4.1 Global Microbiome Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into Microbiome Therapeutics Market
4.4.3 Global Microbiome Therapeutics Companies Product & Service
4.4.4 Upper GIT Revenue Market Share of Microbiome Therapeutics by Company
4.4.5 Lower GIT Revenue Market Share of Microbiome Therapeutics by Company
4.5 Global Microbiome Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Seres Therapeutics
5.1.1 Seres Therapeutics Corporation Information
5.1.2 Seres Therapeutics Description, Business Overview
5.1.3 Seres Therapeutics Microbiome Therapeutics Products Offered
5.1.4 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Seres Therapeutics Microbiome Therapeutics Revenue by Product in 2024
5.1.6 Seres Therapeutics Microbiome Therapeutics Revenue by Application in 2024
5.1.7 Seres Therapeutics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.1.8 Seres Therapeutics Recent Developments
5.2 Assembly Biosciences
5.2.1 Assembly Biosciences Corporation Information
5.2.2 Assembly Biosciences Description, Business Overview
5.2.3 Assembly Biosciences Microbiome Therapeutics Products Offered
5.2.4 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 Assembly Biosciences Microbiome Therapeutics Revenue by Product in 2024
5.2.6 Assembly Biosciences Microbiome Therapeutics Revenue by Application in 2024
5.2.7 Assembly Biosciences Microbiome Therapeutics Revenue by Geographic Area in 2024
5.2.8 Assembly Biosciences Recent Developments
5.3 Synthetic Biologics
5.3.1 Synthetic Biologics Corporation Information
5.3.2 Synthetic Biologics Description, Business Overview
5.3.3 Synthetic Biologics Microbiome Therapeutics Products Offered
5.3.4 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Synthetic Biologics Microbiome Therapeutics Revenue by Product in 2024
5.3.6 Synthetic Biologics Microbiome Therapeutics Revenue by Application in 2024
5.3.7 Synthetic Biologics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.3.8 Synthetic Biologics Recent Developments
5.4 Interxon
5.4.1 Interxon Corporation Information
5.4.2 Interxon Description, Business Overview
5.4.3 Interxon Microbiome Therapeutics Products Offered
5.4.4 Interxon Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 Interxon Microbiome Therapeutics Revenue by Product in 2024
5.4.6 Interxon Microbiome Therapeutics Revenue by Application in 2024
5.4.7 Interxon Microbiome Therapeutics Revenue by Geographic Area in 2024
5.4.8 Interxon Recent Developments
5.5 PureTech
5.5.1 PureTech Corporation Information
5.5.2 PureTech Description, Business Overview
5.5.3 PureTech Microbiome Therapeutics Products Offered
5.5.4 PureTech Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 PureTech Microbiome Therapeutics Revenue by Product in 2024
5.5.6 PureTech Microbiome Therapeutics Revenue by Application in 2024
5.5.7 PureTech Microbiome Therapeutics Revenue by Geographic Area in 2024
5.5.8 PureTech Recent Developments
5.6 Synlogic
5.6.1 Synlogic Corporation Information
5.6.2 Synlogic Description, Business Overview
5.6.3 Synlogic Microbiome Therapeutics Products Offered
5.6.4 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Synlogic Microbiome Therapeutics Revenue by Product in 2024
5.6.6 Synlogic Microbiome Therapeutics Revenue by Application in 2024
5.6.7 Synlogic Microbiome Therapeutics Revenue by Geographic Area in 2024
5.6.8 Synlogic Recent Developments
5.7 Enterome BioScience
5.7.1 Enterome BioScience Corporation Information
5.7.2 Enterome BioScience Description, Business Overview
5.7.3 Enterome BioScience Microbiome Therapeutics Products Offered
5.7.4 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.7.5 Enterome BioScience Microbiome Therapeutics Revenue by Product in 2024
5.7.6 Enterome BioScience Microbiome Therapeutics Revenue by Application in 2024
5.7.7 Enterome BioScience Microbiome Therapeutics Revenue by Geographic Area in 2024
5.7.8 Enterome BioScience Recent Developments
5.8 4D Pharma
5.8.1 4D Pharma Corporation Information
5.8.2 4D Pharma Description, Business Overview
5.8.3 4D Pharma Microbiome Therapeutics Products Offered
5.8.4 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.8.5 4D Pharma Microbiome Therapeutics Revenue by Product in 2024
5.8.6 4D Pharma Microbiome Therapeutics Revenue by Application in 2024
5.8.7 4D Pharma Microbiome Therapeutics Revenue by Geographic Area in 2024
5.8.8 4D Pharma Recent Developments
5.9 Second Genome
5.9.1 Second Genome Corporation Information
5.9.2 Second Genome Description, Business Overview
5.9.3 Second Genome Microbiome Therapeutics Products Offered
5.9.4 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.9.5 Second Genome Microbiome Therapeutics Revenue by Product in 2024
5.9.6 Second Genome Microbiome Therapeutics Revenue by Application in 2024
5.9.7 Second Genome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.9.8 Second Genome Recent Developments
5.10 AOBiome
5.10.1 AOBiome Corporation Information
5.10.2 AOBiome Description, Business Overview
5.10.3 AOBiome Microbiome Therapeutics Products Offered
5.10.4 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.10.5 AOBiome Microbiome Therapeutics Revenue by Product in 2024
5.10.6 AOBiome Microbiome Therapeutics Revenue by Application in 2024
5.10.7 AOBiome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.10.8 AOBiome Recent Developments
5.11 C3 Jian
5.11.1 C3 Jian Corporation Information
5.11.2 C3 Jian Description, Business Overview
5.11.3 C3 Jian Microbiome Therapeutics Products Offered
5.11.4 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.11.5 C3 Jian Microbiome Therapeutics Revenue by Product in 2024
5.11.6 C3 Jian Microbiome Therapeutics Revenue by Application in 2024
5.11.7 C3 Jian Microbiome Therapeutics Revenue by Geographic Area in 2024
5.11.8 C3 Jian Recent Developments
5.12 Rebiotix
5.12.1 Rebiotix Corporation Information
5.12.2 Rebiotix Description, Business Overview
5.12.3 Rebiotix Microbiome Therapeutics Products Offered
5.12.4 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.12.5 Rebiotix Microbiome Therapeutics Revenue by Product in 2024
5.12.6 Rebiotix Microbiome Therapeutics Revenue by Application in 2024
5.12.7 Rebiotix Microbiome Therapeutics Revenue by Geographic Area in 2024
5.12.8 Rebiotix Recent Developments
5.13 MicroBiome Therapeutics LLC
5.13.1 MicroBiome Therapeutics LLC Corporation Information
5.13.2 MicroBiome Therapeutics LLC Description, Business Overview
5.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Products Offered
5.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.13.5 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Product in 2024
5.13.6 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Application in 2024
5.13.7 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Geographic Area in 2024
5.13.8 MicroBiome Therapeutics LLC Recent Developments
5.14 Metabiomics
5.14.1 Metabiomics Corporation Information
5.14.2 Metabiomics Description, Business Overview
5.14.3 Metabiomics Microbiome Therapeutics Products Offered
5.14.4 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.14.5 Metabiomics Microbiome Therapeutics Revenue by Product in 2024
5.14.6 Metabiomics Microbiome Therapeutics Revenue by Application in 2024
5.14.7 Metabiomics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.14.8 Metabiomics Recent Developments
5.15 Ritter Pharmaceuticals
5.15.1 Ritter Pharmaceuticals Corporation Information
5.15.2 Ritter Pharmaceuticals Description, Business Overview
5.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Products Offered
5.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.15.5 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Product in 2024
5.15.6 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Application in 2024
5.15.7 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Geographic Area in 2024
5.15.8 Ritter Pharmaceuticals Recent Developments
5.16 Symberix
5.16.1 Symberix Corporation Information
5.16.2 Symberix Description, Business Overview
5.16.3 Symberix Microbiome Therapeutics Products Offered
5.16.4 Symberix Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.16.5 Symberix Microbiome Therapeutics Revenue by Product in 2024
5.16.6 Symberix Microbiome Therapeutics Revenue by Application in 2024
5.16.7 Symberix Microbiome Therapeutics Revenue by Geographic Area in 2024
5.16.8 Symberix Recent Developments
5.17 OpenBiome
5.17.1 OpenBiome Corporation Information
5.17.2 OpenBiome Description, Business Overview
5.17.3 OpenBiome Microbiome Therapeutics Products Offered
5.17.4 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.17.5 OpenBiome Microbiome Therapeutics Revenue by Product in 2024
5.17.6 OpenBiome Microbiome Therapeutics Revenue by Application in 2024
5.17.7 OpenBiome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.17.8 OpenBiome Recent Developments
5.18 Azitra
5.18.1 Azitra Corporation Information
5.18.2 Azitra Description, Business Overview
5.18.3 Azitra Microbiome Therapeutics Products Offered
5.18.4 Azitra Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.18.5 Azitra Microbiome Therapeutics Revenue by Product in 2024
5.18.6 Azitra Microbiome Therapeutics Revenue by Application in 2024
5.18.7 Azitra Microbiome Therapeutics Revenue by Geographic Area in 2024
5.18.8 Azitra Recent Developments
5.19 Symbiotix Biotherapies
5.19.1 Symbiotix Biotherapies Corporation Information
5.19.2 Symbiotix Biotherapies Description, Business Overview
5.19.3 Symbiotix Biotherapies Microbiome Therapeutics Products Offered
5.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.19.5 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Product in 2024
5.19.6 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Application in 2024
5.19.7 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Geographic Area in 2024
5.19.8 Symbiotix Biotherapies Recent Developments
5.20 Osel
5.20.1 Osel Corporation Information
5.20.2 Osel Description, Business Overview
5.20.3 Osel Microbiome Therapeutics Products Offered
5.20.4 Osel Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.20.5 Osel Microbiome Therapeutics Revenue by Product in 2024
5.20.6 Osel Microbiome Therapeutics Revenue by Application in 2024
5.20.7 Osel Microbiome Therapeutics Revenue by Geographic Area in 2024
5.20.8 Osel Recent Developments
5.21 Metabogen
5.21.1 Metabogen Corporation Information
5.21.2 Metabogen Description, Business Overview
5.21.3 Metabogen Microbiome Therapeutics Products Offered
5.21.4 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.21.5 Metabogen Microbiome Therapeutics Revenue by Product in 2024
5.21.6 Metabogen Microbiome Therapeutics Revenue by Application in 2024
5.21.7 Metabogen Microbiome Therapeutics Revenue by Geographic Area in 2024
5.21.8 Metabogen Recent Developments
6 North America
6.1 North America Microbiome Therapeutics Market Size YoY Growth 2020-2031
6.2 North America Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America Microbiome Therapeutics Revenue by Type (2020-2025)
6.4 North America Microbiome Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Microbiome Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Microbiome Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Microbiome Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific Microbiome Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe Microbiome Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe Microbiome Therapeutics Revenue by Type (2020-2025)
8.4 Europe Microbiome Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Microbiome Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America Microbiome Therapeutics Revenue by Type (2020-2025)
9.4 Latin America Microbiome Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Microbiome Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Microbiome Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa Microbiome Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Microbiome Therapeutics Supply Chain Analysis
11.2 Microbiome Therapeutics Key Raw Materials and Upstream Suppliers
11.3 Microbiome Therapeutics Clients Analysis
11.4 Microbiome Therapeutics Sales Channel and Sales Model Analysis
11.4.1 Microbiome Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Microbiome Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Microbiome Therapeutics Distributors
12 Microbiome Therapeutics Market Dynamics
12.1 Microbiome Therapeutics Industry Trends
12.2 Microbiome Therapeutics Market Drivers
12.3 Microbiome Therapeutics Market Challenges
12.4 Microbiome Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Microbiome Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Microbiome Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Market by Application
1.3.1 Global Microbiome Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Microbiome Therapeutics Market Size Estimates and Forecasts
2.2 Microbiome Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global Microbiome Therapeutics Revenue by Region: 2020-2025
2.2.2 Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Microbiome Therapeutics Revenue by Type (2020-2031)
3.1.2 Global Microbiome Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Microbiome Therapeutics Revenue by Application (2020-2031)
3.2.2 Global Microbiome Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Upper GIT of Microbiome Therapeutics Revenue Market Share by Application
3.3.2 Lower GIT of Microbiome Therapeutics Revenue Market Share by Application
4 Global Microbiome Therapeutics by Company
4.1 Global Microbiome Therapeutics Revenue by Company (2020-2025)
4.2 Global Microbiome Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Microbiome Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Microbiome Therapeutics Companies Headquarters & Product Type
4.4.1 Global Microbiome Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into Microbiome Therapeutics Market
4.4.3 Global Microbiome Therapeutics Companies Product & Service
4.4.4 Upper GIT Revenue Market Share of Microbiome Therapeutics by Company
4.4.5 Lower GIT Revenue Market Share of Microbiome Therapeutics by Company
4.5 Global Microbiome Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Seres Therapeutics
5.1.1 Seres Therapeutics Corporation Information
5.1.2 Seres Therapeutics Description, Business Overview
5.1.3 Seres Therapeutics Microbiome Therapeutics Products Offered
5.1.4 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Seres Therapeutics Microbiome Therapeutics Revenue by Product in 2024
5.1.6 Seres Therapeutics Microbiome Therapeutics Revenue by Application in 2024
5.1.7 Seres Therapeutics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.1.8 Seres Therapeutics Recent Developments
5.2 Assembly Biosciences
5.2.1 Assembly Biosciences Corporation Information
5.2.2 Assembly Biosciences Description, Business Overview
5.2.3 Assembly Biosciences Microbiome Therapeutics Products Offered
5.2.4 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 Assembly Biosciences Microbiome Therapeutics Revenue by Product in 2024
5.2.6 Assembly Biosciences Microbiome Therapeutics Revenue by Application in 2024
5.2.7 Assembly Biosciences Microbiome Therapeutics Revenue by Geographic Area in 2024
5.2.8 Assembly Biosciences Recent Developments
5.3 Synthetic Biologics
5.3.1 Synthetic Biologics Corporation Information
5.3.2 Synthetic Biologics Description, Business Overview
5.3.3 Synthetic Biologics Microbiome Therapeutics Products Offered
5.3.4 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Synthetic Biologics Microbiome Therapeutics Revenue by Product in 2024
5.3.6 Synthetic Biologics Microbiome Therapeutics Revenue by Application in 2024
5.3.7 Synthetic Biologics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.3.8 Synthetic Biologics Recent Developments
5.4 Interxon
5.4.1 Interxon Corporation Information
5.4.2 Interxon Description, Business Overview
5.4.3 Interxon Microbiome Therapeutics Products Offered
5.4.4 Interxon Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 Interxon Microbiome Therapeutics Revenue by Product in 2024
5.4.6 Interxon Microbiome Therapeutics Revenue by Application in 2024
5.4.7 Interxon Microbiome Therapeutics Revenue by Geographic Area in 2024
5.4.8 Interxon Recent Developments
5.5 PureTech
5.5.1 PureTech Corporation Information
5.5.2 PureTech Description, Business Overview
5.5.3 PureTech Microbiome Therapeutics Products Offered
5.5.4 PureTech Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 PureTech Microbiome Therapeutics Revenue by Product in 2024
5.5.6 PureTech Microbiome Therapeutics Revenue by Application in 2024
5.5.7 PureTech Microbiome Therapeutics Revenue by Geographic Area in 2024
5.5.8 PureTech Recent Developments
5.6 Synlogic
5.6.1 Synlogic Corporation Information
5.6.2 Synlogic Description, Business Overview
5.6.3 Synlogic Microbiome Therapeutics Products Offered
5.6.4 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Synlogic Microbiome Therapeutics Revenue by Product in 2024
5.6.6 Synlogic Microbiome Therapeutics Revenue by Application in 2024
5.6.7 Synlogic Microbiome Therapeutics Revenue by Geographic Area in 2024
5.6.8 Synlogic Recent Developments
5.7 Enterome BioScience
5.7.1 Enterome BioScience Corporation Information
5.7.2 Enterome BioScience Description, Business Overview
5.7.3 Enterome BioScience Microbiome Therapeutics Products Offered
5.7.4 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.7.5 Enterome BioScience Microbiome Therapeutics Revenue by Product in 2024
5.7.6 Enterome BioScience Microbiome Therapeutics Revenue by Application in 2024
5.7.7 Enterome BioScience Microbiome Therapeutics Revenue by Geographic Area in 2024
5.7.8 Enterome BioScience Recent Developments
5.8 4D Pharma
5.8.1 4D Pharma Corporation Information
5.8.2 4D Pharma Description, Business Overview
5.8.3 4D Pharma Microbiome Therapeutics Products Offered
5.8.4 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.8.5 4D Pharma Microbiome Therapeutics Revenue by Product in 2024
5.8.6 4D Pharma Microbiome Therapeutics Revenue by Application in 2024
5.8.7 4D Pharma Microbiome Therapeutics Revenue by Geographic Area in 2024
5.8.8 4D Pharma Recent Developments
5.9 Second Genome
5.9.1 Second Genome Corporation Information
5.9.2 Second Genome Description, Business Overview
5.9.3 Second Genome Microbiome Therapeutics Products Offered
5.9.4 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.9.5 Second Genome Microbiome Therapeutics Revenue by Product in 2024
5.9.6 Second Genome Microbiome Therapeutics Revenue by Application in 2024
5.9.7 Second Genome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.9.8 Second Genome Recent Developments
5.10 AOBiome
5.10.1 AOBiome Corporation Information
5.10.2 AOBiome Description, Business Overview
5.10.3 AOBiome Microbiome Therapeutics Products Offered
5.10.4 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.10.5 AOBiome Microbiome Therapeutics Revenue by Product in 2024
5.10.6 AOBiome Microbiome Therapeutics Revenue by Application in 2024
5.10.7 AOBiome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.10.8 AOBiome Recent Developments
5.11 C3 Jian
5.11.1 C3 Jian Corporation Information
5.11.2 C3 Jian Description, Business Overview
5.11.3 C3 Jian Microbiome Therapeutics Products Offered
5.11.4 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.11.5 C3 Jian Microbiome Therapeutics Revenue by Product in 2024
5.11.6 C3 Jian Microbiome Therapeutics Revenue by Application in 2024
5.11.7 C3 Jian Microbiome Therapeutics Revenue by Geographic Area in 2024
5.11.8 C3 Jian Recent Developments
5.12 Rebiotix
5.12.1 Rebiotix Corporation Information
5.12.2 Rebiotix Description, Business Overview
5.12.3 Rebiotix Microbiome Therapeutics Products Offered
5.12.4 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.12.5 Rebiotix Microbiome Therapeutics Revenue by Product in 2024
5.12.6 Rebiotix Microbiome Therapeutics Revenue by Application in 2024
5.12.7 Rebiotix Microbiome Therapeutics Revenue by Geographic Area in 2024
5.12.8 Rebiotix Recent Developments
5.13 MicroBiome Therapeutics LLC
5.13.1 MicroBiome Therapeutics LLC Corporation Information
5.13.2 MicroBiome Therapeutics LLC Description, Business Overview
5.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Products Offered
5.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.13.5 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Product in 2024
5.13.6 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Application in 2024
5.13.7 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue by Geographic Area in 2024
5.13.8 MicroBiome Therapeutics LLC Recent Developments
5.14 Metabiomics
5.14.1 Metabiomics Corporation Information
5.14.2 Metabiomics Description, Business Overview
5.14.3 Metabiomics Microbiome Therapeutics Products Offered
5.14.4 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.14.5 Metabiomics Microbiome Therapeutics Revenue by Product in 2024
5.14.6 Metabiomics Microbiome Therapeutics Revenue by Application in 2024
5.14.7 Metabiomics Microbiome Therapeutics Revenue by Geographic Area in 2024
5.14.8 Metabiomics Recent Developments
5.15 Ritter Pharmaceuticals
5.15.1 Ritter Pharmaceuticals Corporation Information
5.15.2 Ritter Pharmaceuticals Description, Business Overview
5.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Products Offered
5.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.15.5 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Product in 2024
5.15.6 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Application in 2024
5.15.7 Ritter Pharmaceuticals Microbiome Therapeutics Revenue by Geographic Area in 2024
5.15.8 Ritter Pharmaceuticals Recent Developments
5.16 Symberix
5.16.1 Symberix Corporation Information
5.16.2 Symberix Description, Business Overview
5.16.3 Symberix Microbiome Therapeutics Products Offered
5.16.4 Symberix Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.16.5 Symberix Microbiome Therapeutics Revenue by Product in 2024
5.16.6 Symberix Microbiome Therapeutics Revenue by Application in 2024
5.16.7 Symberix Microbiome Therapeutics Revenue by Geographic Area in 2024
5.16.8 Symberix Recent Developments
5.17 OpenBiome
5.17.1 OpenBiome Corporation Information
5.17.2 OpenBiome Description, Business Overview
5.17.3 OpenBiome Microbiome Therapeutics Products Offered
5.17.4 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.17.5 OpenBiome Microbiome Therapeutics Revenue by Product in 2024
5.17.6 OpenBiome Microbiome Therapeutics Revenue by Application in 2024
5.17.7 OpenBiome Microbiome Therapeutics Revenue by Geographic Area in 2024
5.17.8 OpenBiome Recent Developments
5.18 Azitra
5.18.1 Azitra Corporation Information
5.18.2 Azitra Description, Business Overview
5.18.3 Azitra Microbiome Therapeutics Products Offered
5.18.4 Azitra Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.18.5 Azitra Microbiome Therapeutics Revenue by Product in 2024
5.18.6 Azitra Microbiome Therapeutics Revenue by Application in 2024
5.18.7 Azitra Microbiome Therapeutics Revenue by Geographic Area in 2024
5.18.8 Azitra Recent Developments
5.19 Symbiotix Biotherapies
5.19.1 Symbiotix Biotherapies Corporation Information
5.19.2 Symbiotix Biotherapies Description, Business Overview
5.19.3 Symbiotix Biotherapies Microbiome Therapeutics Products Offered
5.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.19.5 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Product in 2024
5.19.6 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Application in 2024
5.19.7 Symbiotix Biotherapies Microbiome Therapeutics Revenue by Geographic Area in 2024
5.19.8 Symbiotix Biotherapies Recent Developments
5.20 Osel
5.20.1 Osel Corporation Information
5.20.2 Osel Description, Business Overview
5.20.3 Osel Microbiome Therapeutics Products Offered
5.20.4 Osel Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.20.5 Osel Microbiome Therapeutics Revenue by Product in 2024
5.20.6 Osel Microbiome Therapeutics Revenue by Application in 2024
5.20.7 Osel Microbiome Therapeutics Revenue by Geographic Area in 2024
5.20.8 Osel Recent Developments
5.21 Metabogen
5.21.1 Metabogen Corporation Information
5.21.2 Metabogen Description, Business Overview
5.21.3 Metabogen Microbiome Therapeutics Products Offered
5.21.4 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2020-2025)
5.21.5 Metabogen Microbiome Therapeutics Revenue by Product in 2024
5.21.6 Metabogen Microbiome Therapeutics Revenue by Application in 2024
5.21.7 Metabogen Microbiome Therapeutics Revenue by Geographic Area in 2024
5.21.8 Metabogen Recent Developments
6 North America
6.1 North America Microbiome Therapeutics Market Size YoY Growth 2020-2031
6.2 North America Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America Microbiome Therapeutics Revenue by Type (2020-2025)
6.4 North America Microbiome Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Microbiome Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Microbiome Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Microbiome Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific Microbiome Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe Microbiome Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe Microbiome Therapeutics Revenue by Type (2020-2025)
8.4 Europe Microbiome Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Microbiome Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America Microbiome Therapeutics Revenue by Type (2020-2025)
9.4 Latin America Microbiome Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Microbiome Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Microbiome Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Microbiome Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa Microbiome Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Microbiome Therapeutics Supply Chain Analysis
11.2 Microbiome Therapeutics Key Raw Materials and Upstream Suppliers
11.3 Microbiome Therapeutics Clients Analysis
11.4 Microbiome Therapeutics Sales Channel and Sales Model Analysis
11.4.1 Microbiome Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Microbiome Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Microbiome Therapeutics Distributors
12 Microbiome Therapeutics Market Dynamics
12.1 Microbiome Therapeutics Industry Trends
12.2 Microbiome Therapeutics Market Drivers
12.3 Microbiome Therapeutics Market Challenges
12.4 Microbiome Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Microbiome Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Microbiome Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Microbiome Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Microbiome Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Microbiome Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Microbiome Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 11. Microbiome Therapeutics Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Microbiome Therapeutics Players by Revenue (US$ Million) in 2024
Table 13. Global Microbiome Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Table 15. Global Microbiome Therapeutics Companies Headquarters
Table 16. Date of International Companies Enter into Microbiome Therapeutics Market
Table 17. Global Microbiome Therapeutics Companies Product & Service
Table 18. Global Microbiome Therapeutics Mergers & Acquisitions, Expansion Plans
Table 19. Seres Therapeutics Corporation Information
Table 20. Seres Therapeutics Description and Business Overview
Table 21. Seres Therapeutics Microbiome Therapeutics Product
Table 22. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 24. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 25. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 26. Seres Therapeutics Recent Developments
Table 27. Assembly Biosciences Corporation Information
Table 28. Assembly Biosciences Description and Business Overview
Table 29. Assembly Biosciences Microbiome Therapeutics Product
Table 30. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 32. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 33. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 34. Assembly Biosciences Recent Developments
Table 35. Synthetic Biologics Corporation Information
Table 36. Synthetic Biologics Description and Business Overview
Table 37. Synthetic Biologics Microbiome Therapeutics Product
Table 38. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 40. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 41. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 42. Synthetic Biologics Recent Developments
Table 43. Interxon Corporation Information
Table 44. Interxon Description and Business Overview
Table 45. Interxon Microbiome Therapeutics Product
Table 46. Interxon Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Interxon Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 48. Interxon Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 49. Interxon Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 50. Interxon Recent Developments
Table 51. PureTech Corporation Information
Table 52. PureTech Description and Business Overview
Table 53. PureTech Microbiome Therapeutics Product
Table 54. PureTech Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. PureTech Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 56. PureTech Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 57. PureTech Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 58. PureTech Recent Developments
Table 59. Synlogic Corporation Information
Table 60. Synlogic Description and Business Overview
Table 61. Synlogic Microbiome Therapeutics Product
Table 62. Synlogic Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Synlogic Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 64. Synlogic Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 65. Synlogic Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 66. Synlogic Recent Developments
Table 67. Enterome BioScience Corporation Information
Table 68. Enterome BioScience Description and Business Overview
Table 69. Enterome BioScience Microbiome Therapeutics Product
Table 70. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 72. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 73. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 74. Enterome BioScience Recent Developments
Table 75. 4D Pharma Corporation Information
Table 76. 4D Pharma Description and Business Overview
Table 77. 4D Pharma Microbiome Therapeutics Product
Table 78. 4D Pharma Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 80. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 81. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 82. 4D Pharma Recent Developments
Table 83. Second Genome Corporation Information
Table 84. Second Genome Description and Business Overview
Table 85. Second Genome Microbiome Therapeutics Product
Table 86. Second Genome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Second Genome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 88. Second Genome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 89. Second Genome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 90. Second Genome Recent Developments
Table 91. AOBiome Corporation Information
Table 92. AOBiome Description and Business Overview
Table 93. AOBiome Microbiome Therapeutics Product
Table 94. AOBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. AOBiome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 96. AOBiome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 97. AOBiome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 98. AOBiome Recent Developments
Table 99. C3 Jian Corporation Information
Table 100. C3 Jian Description and Business Overview
Table 101. C3 Jian Microbiome Therapeutics Product
Table 102. C3 Jian Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. C3 Jian Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 104. C3 Jian Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 105. C3 Jian Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 106. C3 Jian Recent Developments
Table 107. Rebiotix Corporation Information
Table 108. Rebiotix Description and Business Overview
Table 109. Rebiotix Microbiome Therapeutics Product
Table 110. Rebiotix Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Rebiotix Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 112. Rebiotix Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 113. Rebiotix Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 114. Rebiotix Recent Developments
Table 115. MicroBiome Therapeutics LLC Corporation Information
Table 116. MicroBiome Therapeutics LLC Description and Business Overview
Table 117. MicroBiome Therapeutics LLC Microbiome Therapeutics Product
Table 118. MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 120. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 121. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 122. MicroBiome Therapeutics LLC Recent Developments
Table 123. Metabiomics Corporation Information
Table 124. Metabiomics Description and Business Overview
Table 125. Metabiomics Microbiome Therapeutics Product
Table 126. Metabiomics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Metabiomics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 128. Metabiomics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 129. Metabiomics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 130. Metabiomics Recent Developments
Table 131. Ritter Pharmaceuticals Corporation Information
Table 132. Ritter Pharmaceuticals Description and Business Overview
Table 133. Ritter Pharmaceuticals Microbiome Therapeutics Product
Table 134. Ritter Pharmaceuticals Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 136. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 137. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 138. Ritter Pharmaceuticals Recent Developments
Table 139. Symberix Corporation Information
Table 140. Symberix Description and Business Overview
Table 141. Symberix Microbiome Therapeutics Product
Table 142. Symberix Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Symberix Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 144. Symberix Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 145. Symberix Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 146. Symberix Recent Developments
Table 147. OpenBiome Corporation Information
Table 148. OpenBiome Description and Business Overview
Table 149. OpenBiome Microbiome Therapeutics Product
Table 150. OpenBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. OpenBiome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 152. OpenBiome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 153. OpenBiome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 154. OpenBiome Recent Developments
Table 155. Azitra Corporation Information
Table 156. Azitra Description and Business Overview
Table 157. Azitra Microbiome Therapeutics Product
Table 158. Azitra Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 159. Azitra Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 160. Azitra Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 161. Azitra Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 162. Azitra Recent Developments
Table 163. Symbiotix Biotherapies Corporation Information
Table 164. Symbiotix Biotherapies Description and Business Overview
Table 165. Symbiotix Biotherapies Microbiome Therapeutics Product
Table 166. Symbiotix Biotherapies Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 167. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 168. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 169. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 170. Symbiotix Biotherapies Recent Developments
Table 171. Osel Corporation Information
Table 172. Osel Description and Business Overview
Table 173. Osel Microbiome Therapeutics Product
Table 174. Osel Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 175. Osel Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 176. Osel Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 177. Osel Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 178. Osel Recent Developments
Table 179. Metabogen Corporation Information
Table 180. Metabogen Description and Business Overview
Table 181. Metabogen Microbiome Therapeutics Product
Table 182. Metabogen Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Metabogen Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 184. Metabogen Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 185. Metabogen Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 186. Metabogen Recent Developments
Table 187. North America Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 188. North America Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 189. North America Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 190. North America Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 191. Asia-Pacific Microbiome Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 192. Asia-Pacific Microbiome Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 193. Asia-Pacific Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 194. Asia-Pacific Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 195. Europe Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 196. Europe Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 197. Europe Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 198. Europe Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 199. Latin America Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 200. Latin America Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 201. Latin America Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 202. Latin America Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 203. Middle East and Africa Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 204. Middle East and Africa Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 205. Middle East and Africa Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 206. Middle East and Africa Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 207. Microbiome Therapeutics Key Raw Materials, Industry Status and Trend
Table 208. Microbiome Therapeutics Key Raw Materials and Upstream Suppliers
Table 209. Microbiome Therapeutics Clients Status and Trend
Table 210. Microbiome Therapeutics Typical Clients
Table 211. Microbiome Therapeutics Distributors
Table 212. Microbiome Therapeutics Market Trends
Table 213. Microbiome Therapeutics Market Drivers
Table 214. Microbiome Therapeutics Market Challenges
Table 215. Microbiome Therapeutics Market Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Microbiome Therapeutics Revenue Market Share by Type in 2024 & 2031
Figure 4. Upper GIT Product Picture
Figure 5. Lower GIT Product Picture
Figure 6. Global Microbiome Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Microbiome Therapeutics Revenue Market Share by Application in 2024 & 2031
Figure 8. C. difficile Infection (CDI)
Figure 9. Inflammatory Bowel Disease (IBD)
Figure 10. Orphan Drug
Figure 11. Immuno-oncology
Figure 12. Others
Figure 13. Microbiome Therapeutics Report Years Considered
Figure 14. Global Microbiome Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Microbiome Therapeutics Market Size (2020-2031) & (US$ Million)
Figure 16. Global Microbiome Therapeutics Market Size Market Share by Region: 2024 Versus 2031
Figure 17. Global Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
Figure 18. Global Microbiome Therapeutics Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Global Microbiome Therapeutics Revenue Market Share Forecast by Application (2020-2031)
Figure 20. Upper GIT of Microbiome Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 21. Lower GIT of Microbiome Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 22. Microbiome Therapeutics Revenue Share by Company (2024)
Figure 23. Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Upper GIT Revenue Proportion by Company in 2024
Figure 25. Lower GIT Revenue Proportion by Company in 2024
Figure 26. North America Microbiome Therapeutics Revenue 2020-2031 (US$ Million)
Figure 27. North America Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 28. North America Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Microbiome Therapeutics Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 33. Europe Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 35. Europe Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 36. Europe Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 45. Microbiome Therapeutics Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Microbiome Therapeutics Raw Materials by Region in 2024
Figure 47. Microbiome Therapeutics Distribution Channels
Figure 48. Global Microbiome Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Microbiome Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Table 1. Global Microbiome Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Microbiome Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Microbiome Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Microbiome Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Microbiome Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Microbiome Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 11. Microbiome Therapeutics Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Microbiome Therapeutics Players by Revenue (US$ Million) in 2024
Table 13. Global Microbiome Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Table 15. Global Microbiome Therapeutics Companies Headquarters
Table 16. Date of International Companies Enter into Microbiome Therapeutics Market
Table 17. Global Microbiome Therapeutics Companies Product & Service
Table 18. Global Microbiome Therapeutics Mergers & Acquisitions, Expansion Plans
Table 19. Seres Therapeutics Corporation Information
Table 20. Seres Therapeutics Description and Business Overview
Table 21. Seres Therapeutics Microbiome Therapeutics Product
Table 22. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 24. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 25. Seres Therapeutics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 26. Seres Therapeutics Recent Developments
Table 27. Assembly Biosciences Corporation Information
Table 28. Assembly Biosciences Description and Business Overview
Table 29. Assembly Biosciences Microbiome Therapeutics Product
Table 30. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 32. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 33. Assembly Biosciences Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 34. Assembly Biosciences Recent Developments
Table 35. Synthetic Biologics Corporation Information
Table 36. Synthetic Biologics Description and Business Overview
Table 37. Synthetic Biologics Microbiome Therapeutics Product
Table 38. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 40. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 41. Synthetic Biologics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 42. Synthetic Biologics Recent Developments
Table 43. Interxon Corporation Information
Table 44. Interxon Description and Business Overview
Table 45. Interxon Microbiome Therapeutics Product
Table 46. Interxon Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Interxon Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 48. Interxon Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 49. Interxon Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 50. Interxon Recent Developments
Table 51. PureTech Corporation Information
Table 52. PureTech Description and Business Overview
Table 53. PureTech Microbiome Therapeutics Product
Table 54. PureTech Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. PureTech Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 56. PureTech Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 57. PureTech Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 58. PureTech Recent Developments
Table 59. Synlogic Corporation Information
Table 60. Synlogic Description and Business Overview
Table 61. Synlogic Microbiome Therapeutics Product
Table 62. Synlogic Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Synlogic Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 64. Synlogic Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 65. Synlogic Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 66. Synlogic Recent Developments
Table 67. Enterome BioScience Corporation Information
Table 68. Enterome BioScience Description and Business Overview
Table 69. Enterome BioScience Microbiome Therapeutics Product
Table 70. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 72. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 73. Enterome BioScience Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 74. Enterome BioScience Recent Developments
Table 75. 4D Pharma Corporation Information
Table 76. 4D Pharma Description and Business Overview
Table 77. 4D Pharma Microbiome Therapeutics Product
Table 78. 4D Pharma Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 80. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 81. 4D Pharma Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 82. 4D Pharma Recent Developments
Table 83. Second Genome Corporation Information
Table 84. Second Genome Description and Business Overview
Table 85. Second Genome Microbiome Therapeutics Product
Table 86. Second Genome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Second Genome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 88. Second Genome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 89. Second Genome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 90. Second Genome Recent Developments
Table 91. AOBiome Corporation Information
Table 92. AOBiome Description and Business Overview
Table 93. AOBiome Microbiome Therapeutics Product
Table 94. AOBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. AOBiome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 96. AOBiome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 97. AOBiome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 98. AOBiome Recent Developments
Table 99. C3 Jian Corporation Information
Table 100. C3 Jian Description and Business Overview
Table 101. C3 Jian Microbiome Therapeutics Product
Table 102. C3 Jian Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. C3 Jian Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 104. C3 Jian Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 105. C3 Jian Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 106. C3 Jian Recent Developments
Table 107. Rebiotix Corporation Information
Table 108. Rebiotix Description and Business Overview
Table 109. Rebiotix Microbiome Therapeutics Product
Table 110. Rebiotix Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Rebiotix Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 112. Rebiotix Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 113. Rebiotix Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 114. Rebiotix Recent Developments
Table 115. MicroBiome Therapeutics LLC Corporation Information
Table 116. MicroBiome Therapeutics LLC Description and Business Overview
Table 117. MicroBiome Therapeutics LLC Microbiome Therapeutics Product
Table 118. MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 120. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 121. MicroBiome Therapeutics LLC Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 122. MicroBiome Therapeutics LLC Recent Developments
Table 123. Metabiomics Corporation Information
Table 124. Metabiomics Description and Business Overview
Table 125. Metabiomics Microbiome Therapeutics Product
Table 126. Metabiomics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Metabiomics Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 128. Metabiomics Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 129. Metabiomics Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 130. Metabiomics Recent Developments
Table 131. Ritter Pharmaceuticals Corporation Information
Table 132. Ritter Pharmaceuticals Description and Business Overview
Table 133. Ritter Pharmaceuticals Microbiome Therapeutics Product
Table 134. Ritter Pharmaceuticals Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 136. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 137. Ritter Pharmaceuticals Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 138. Ritter Pharmaceuticals Recent Developments
Table 139. Symberix Corporation Information
Table 140. Symberix Description and Business Overview
Table 141. Symberix Microbiome Therapeutics Product
Table 142. Symberix Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Symberix Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 144. Symberix Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 145. Symberix Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 146. Symberix Recent Developments
Table 147. OpenBiome Corporation Information
Table 148. OpenBiome Description and Business Overview
Table 149. OpenBiome Microbiome Therapeutics Product
Table 150. OpenBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. OpenBiome Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 152. OpenBiome Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 153. OpenBiome Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 154. OpenBiome Recent Developments
Table 155. Azitra Corporation Information
Table 156. Azitra Description and Business Overview
Table 157. Azitra Microbiome Therapeutics Product
Table 158. Azitra Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 159. Azitra Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 160. Azitra Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 161. Azitra Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 162. Azitra Recent Developments
Table 163. Symbiotix Biotherapies Corporation Information
Table 164. Symbiotix Biotherapies Description and Business Overview
Table 165. Symbiotix Biotherapies Microbiome Therapeutics Product
Table 166. Symbiotix Biotherapies Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 167. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 168. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 169. Symbiotix Biotherapies Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 170. Symbiotix Biotherapies Recent Developments
Table 171. Osel Corporation Information
Table 172. Osel Description and Business Overview
Table 173. Osel Microbiome Therapeutics Product
Table 174. Osel Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 175. Osel Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 176. Osel Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 177. Osel Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 178. Osel Recent Developments
Table 179. Metabogen Corporation Information
Table 180. Metabogen Description and Business Overview
Table 181. Metabogen Microbiome Therapeutics Product
Table 182. Metabogen Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Metabogen Revenue Proportion of Microbiome Therapeutics by Product in 2024
Table 184. Metabogen Revenue Proportion of Microbiome Therapeutics by Application in 2024
Table 185. Metabogen Revenue Proportion of Microbiome Therapeutics by Geographic Area in 2024
Table 186. Metabogen Recent Developments
Table 187. North America Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 188. North America Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 189. North America Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 190. North America Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 191. Asia-Pacific Microbiome Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 192. Asia-Pacific Microbiome Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 193. Asia-Pacific Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 194. Asia-Pacific Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 195. Europe Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 196. Europe Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 197. Europe Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 198. Europe Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 199. Latin America Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 200. Latin America Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 201. Latin America Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 202. Latin America Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 203. Middle East and Africa Microbiome Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 204. Middle East and Africa Microbiome Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 205. Middle East and Africa Microbiome Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 206. Middle East and Africa Microbiome Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 207. Microbiome Therapeutics Key Raw Materials, Industry Status and Trend
Table 208. Microbiome Therapeutics Key Raw Materials and Upstream Suppliers
Table 209. Microbiome Therapeutics Clients Status and Trend
Table 210. Microbiome Therapeutics Typical Clients
Table 211. Microbiome Therapeutics Distributors
Table 212. Microbiome Therapeutics Market Trends
Table 213. Microbiome Therapeutics Market Drivers
Table 214. Microbiome Therapeutics Market Challenges
Table 215. Microbiome Therapeutics Market Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Microbiome Therapeutics Revenue Market Share by Type in 2024 & 2031
Figure 4. Upper GIT Product Picture
Figure 5. Lower GIT Product Picture
Figure 6. Global Microbiome Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Microbiome Therapeutics Revenue Market Share by Application in 2024 & 2031
Figure 8. C. difficile Infection (CDI)
Figure 9. Inflammatory Bowel Disease (IBD)
Figure 10. Orphan Drug
Figure 11. Immuno-oncology
Figure 12. Others
Figure 13. Microbiome Therapeutics Report Years Considered
Figure 14. Global Microbiome Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Microbiome Therapeutics Market Size (2020-2031) & (US$ Million)
Figure 16. Global Microbiome Therapeutics Market Size Market Share by Region: 2024 Versus 2031
Figure 17. Global Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
Figure 18. Global Microbiome Therapeutics Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Global Microbiome Therapeutics Revenue Market Share Forecast by Application (2020-2031)
Figure 20. Upper GIT of Microbiome Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 21. Lower GIT of Microbiome Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 22. Microbiome Therapeutics Revenue Share by Company (2024)
Figure 23. Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Upper GIT Revenue Proportion by Company in 2024
Figure 25. Lower GIT Revenue Proportion by Company in 2024
Figure 26. North America Microbiome Therapeutics Revenue 2020-2031 (US$ Million)
Figure 27. North America Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 28. North America Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Microbiome Therapeutics Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 33. Europe Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 35. Europe Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 36. Europe Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Microbiome Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Figure 45. Microbiome Therapeutics Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Microbiome Therapeutics Raw Materials by Region in 2024
Figure 47. Microbiome Therapeutics Distribution Channels
Figure 48. Global Microbiome Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Microbiome Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232